GENEVA - Swiss drug maker Roche Holding AG has reported a 7 per cent rise in core operating profit to 8.6 billion Swiss francs in the first half, helped by sales of cancer drugs and recent cost-cutting.
The Basel, Switzerland-based company's half-year results also show that excluding the effect of the strong Swiss currency its group sales rose 4 per cent to 22.4 billion francs.
The company's results issued Thursday before the opening of the Zurich exchange said that its net income fell 14 per cent mainly due to one-off costs from the closure of its Nutley, New Jersey, site.
The former U.S. headquarters is to be closed by the end of 2013 in a money-saving consolidation of research and development programs.
Roche also confirmed its full-year outlook for sales in low to middle single-digit rates.